EN DE
Watch Sansure Biotech Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sansure Biotech Inc (688289) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Sansure Biotech Inc stock ¥14.87, price ¥15.79, that is 5.8% below the price, quality 54 out of 100. Rating: fairly valued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000043J1

SB Sansure Biotech Inc logo Thin data Nov 7, 2026

Sansure Biotech Inc

688289 · SHG
Fairly valued, in a downtrend

The stock costs about what our calculation considers fair.

Low debt
Fair value ¥14.87 · Fairly valued
Quality 54/100
Mixed Growth (revenue 3y −36.5 %/yr in CNY)
Thin margins · 8.4% net margin (TTM)
Costs 69 times its yearly profit.
Negative free cash flow
3.3% dividend yield · Pays more than it earns
Trails peers (3/13)
Narrow moat 28/100 · thin data
Thin data
Watch Sansure Biotech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥57.22 ¥13.44 Fair Value ¥14.87 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥13.44 – ¥57.22 · fair‑value band ¥14.18 – ¥15.44 · the ¥15.79 price screens above the ¥14.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Sansure Biotech in your weekly email

Every Wednesday you see whether Sansure Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally.

Show moreShow less

It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; and diagnostic kits for monkeypox, epstein-barr virus, and human cytomegalovirus DNA, as well as rapid antigen tests.

The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems.

In addition, it engages in the research and development, production, and sale of drugs; procurement and sale of raw materials; manufacture of instruments; manufacture and sale of electronic equipment; trading; investment consulting; medical research and experimental development; and internet sales, as well as offers third-party medical testing and biotechnology development services.

The company was founded in 2008 and is headquartered in Changsha, China.

Stock analysis

Sansure Biotech Inc (688289) currently trades at ¥15.79, while our model-based Fair Value estimate is ¥14.87, so the stock looks roughly fairly valued today (gap 6.2%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥12.54 per share, and 2 of the 14 models we run sit above the ¥15.79 price.

Bear case: the Asset-Based group reads lowest at ¥5.16, and 12 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥14.18 (bear) to ¥15.44 (bull), the price of ¥15.79 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2022: revenue and profit before it include the divested business. Growth is measured afresh from 2022.

Sansure Biotech Inc reported revenue of 1.6B CNY in FY2025 versus 4.5B CNY in FY2021, a compound −22.3%/yr. Reported net income was 198M CNY in FY2025, compounding −45.5%/yr from FY2021.

Key figures

Market cap 9.2B CNY (≈ $1.4B) Small · P/E ratio 68.7 · P/S ratio 5.73 · EPS (TTM) ¥0.2300 · Dividend yield 3.3% · Net margin 8.4% · Return on equity 1.3% · Return on assets (EBIT) 14.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −6%, 688289 screens cheaper than that median.

Fair Value models

Bear ¥14.18 Fair Value ¥14.87 Bull ¥15.44
Price ¥15.79 · Downside -5.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥8.43 ¥8.45 ¥8.74 76
EPV ¥7.88 ¥8.26 ¥8.58 74
ROIC Compounder ¥7.88 ¥8.26 ¥8.58 72
All 14 models by family
Earnings-Based
Graham-Dodd ¥2.34 ¥3.98 ¥4.86 67
EPV ¥7.88 ¥8.26 ¥8.58 74
Dividend Discount
Gordon GGM ¥4.72 ¥5.75 ¥6.77 69
DDM Multi-Stage ¥4.72 ¥6.10 ¥7.65 67
Multiples
P/E Multiple ¥5.69 ¥7.58 ¥9.48 63
P/S Multiple ¥4.39 ¥5.86 ¥7.32 58
P/B Multiple ¥34.05 ¥45.40 ¥56.76 55
EV/EBIT ¥11.75 ¥13.24 ¥14.74 66
EV/EBITDA ¥14.82 ¥17.34 ¥19.86 67
EV/Revenue ¥10.46 ¥11.83 ¥13.21 54
Asset-Based
NCAV (Graham) ¥3.41 ¥5.16 ¥6.45 55
Economic Profit
Residual Income ¥8.43 ¥8.45 ¥8.74 76
ROIC Compounder ¥7.88 ¥8.26 ¥8.58 72
Growth Earnings
Growth-Adj P/E ¥4.01 ¥5.73 ¥7.44 67

The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 28
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 65
Does it invest with discipline instead of growing at any price?
Low Volatility 78
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 85
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2022: revenue and profit before it include the divested business. Growth is measured afresh from 2022.
Revenue growth 1 year
+13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−30.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−33.3%
Dividend (yield on the price)3.3%
Per share before 2022divided by the spin-off factor 1.48
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.65% → 12%

Watch 688289, get fair value alerts →

Compare Sansure Biotech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside −5.8% · Above median
Profitability
Return on equity (12 months) 1.3% · Bottom 25%
Return on assets 2.1% · Below median
Net margin (12 months) 8.4% · Below median
Operating margin (12 months) −3.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 1.0% · Below median
Dividend yield (12 months) 3.3% · Top 25%
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 68.7× · Priciest 25%
P/B 1.27× · Cheaper than median
P/S (12 months) 5.73× · Priciest 25%
EV/EBITDA 23.7× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)26 · sector 25
FUTURE (revenue growth)5 · sector 40
PAST (return on equity)5 · sector 30
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)67 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs 688289
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs 688289
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs 688289
Medline Inc MDLN $39.64 $28.59 −28% vs 688289
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs 688289
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs 688289
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs 688289
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs 688289
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs 688289
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs 688289

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sansure Biotech Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sansure Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/688289

Frequently asked questions

Is Sansure Biotech Inc (688289) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥14.87 versus a price of ¥15.79, about 6% lower (fairly valued).
What is the fair value of 688289?
Our model-based fair value for Sansure Biotech Inc is ¥14.87 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥15.79.
What is the quality score of 688289?
Sansure Biotech Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sansure Biotech Inc (688289)?
Our model-based price target is the fair value of ¥14.87 (as of Nov 7, 2026) from 14 valuation models. Cautious scenario ¥14.18, optimistic scenario ¥15.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Sansure Biotech Inc stock forecast for 2026?
Our models put fair value at ¥14.87, about 6% lower versus a price of ¥15.79 (fairly valued). Cautious scenario ¥14.18, optimistic scenario ¥15.44. The calculation is refreshed regularly with new filings.
What is the revenue of Sansure Biotech Inc (688289)?
Sansure Biotech Inc reported trailing-twelve-month revenue of about 1.6B CNY (latest available figure, as of Nov 7, 2026).
Does Sansure Biotech Inc pay a dividend?
Sansure Biotech Inc currently shows a dividend yield of 3.33% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Sansure Biotech Inc (688289) and when is the ex-dividend date?
Sansure Biotech Inc pays a dividend of ¥0.526 per share a year, a dividend yield of 3.3%. The last ex-dividend date was Oct 15, 2026. A dividend has been paid every year since at least 2020. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Sansure Biotech Inc (688289)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sansure Biotech Inc it is ¥14.87 per share (as of Nov 7, 2026), against a price of ¥15.79. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Sansure Biotech Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 688289 trades above its calculated fair value: price ¥15.79, fair value ¥14.87, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688289?
No. The price is what the market pays today (¥15.79); the fair value is what the company's own numbers justify (¥14.87). For Sansure Biotech Inc the two are ¥0.9220 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sansure Biotech Inc worth?
The market values Sansure Biotech Inc at about 9.2B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥15.79; our models calculate a fair value of ¥14.87 per share.
What do the bullish and bearish scenarios say about 688289?
Our models span a range for Sansure Biotech Inc: cautious scenario ¥14.18, base ¥14.87, optimistic ¥15.44 per share (as of Nov 7, 2026, price ¥15.79). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688289?
Sansure Biotech Inc trades at a price-to-earnings ratio of 68.7 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥14.87 is built from several models across several years. Other multiples: P/B 1.3, P/S 5.7, EV/EBITDA 23.7.
How solid is the balance sheet of Sansure Biotech Inc (688289)?
Balance-sheet figures for Sansure Biotech Inc (as of Nov 7, 2026): return on equity 1.3%, debt of 0.13 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 688289 from its 52-week high?
Sansure Biotech Inc trades at ¥15.79, about 26% below its 52-week high of ¥21.36 and 16% above the low of ¥13.64 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥14.87 is for.
Which stocks are comparable to Sansure Biotech Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sansure Biotech Inc stock attractive at the current price?
The data as of Nov 7, 2026: price ¥15.79, calculated fair value ¥14.87 (−6%), Quality Score 54/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688289 calculated?
We run Sansure Biotech Inc through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥14.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sansure Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sansure Biotech Inc (688289)?
The closing price on Nov 6, 2026 was ¥15.79. Our model-based fair value is ¥14.87, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sansure Biotech Inc right now?
The price sits above even our optimistic bull case (¥15.44). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (¥14.18 to ¥15.44), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sansure Biotech Inc

How large is the market capitalisation of Sansure Biotech Inc (688289)?
The market capitalisation of Sansure Biotech Inc is 9.2B CNY (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sansure Biotech Inc (688289)?
The price-to-sales ratio of Sansure Biotech Inc is 5.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sansure Biotech Inc (688289)?
Earnings per share at Sansure Biotech Inc are ¥0.2300 (price ÷ EPS = P/E 68.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sansure Biotech Inc (688289)?
The dividend yield of Sansure Biotech Inc is 3.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sansure Biotech Inc (688289)?
The net margin of Sansure Biotech Inc is 8.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sansure Biotech Inc (688289)?
The return on equity (ROE) of Sansure Biotech Inc is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sansure Biotech Inc (688289)?
On an EBIT basis the return on assets of Sansure Biotech Inc is 14.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sansure Biotech Inc (688289)?
The operating margin of Sansure Biotech Inc is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sansure Biotech Inc (688289)?
Revenue at Sansure Biotech Inc is growing +1.0% versus a year earlier (3y avg −36.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sansure Biotech Inc (688289)?
Earnings per share at Sansure Biotech Inc are growing −24.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sansure Biotech Inc (688289) generate?
The free cash flow of Sansure Biotech Inc is −186M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sansure Biotech Inc (688289) hold?
Sansure Biotech Inc holds more cash than debt, 4.2B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sansure Biotech Inc in the live analysis

One click puts Sansure Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.